Novavax's protein vaccine against Covid-19 (Nuvaxovid) is approved in Switzerland. Novavax tested its vaccine in a total of more than 40,000 people. In these studies, the vaccine showed a protective effect against Covid-19 infection of 90%. In addition, no severe courses of disease were observed in the vaccinated individuals in the study. However, very few severe cases occurred overall in the study. Therefore, it cannot be reliably assessed how well the vaccine can prevent severe courses of disease.
How well Novavax's vaccine protects against the new is not yet known and is under ongoing investigation. Novavax is also in the process of developing a vaccine specifically adapted to the Omicron variant.